S Gastrointestinal And Liver Disease 12th Edition __exclusive__ -
A new chapter dedicated to the role of the gut microbiome in health and disease, plus integrated discussions on fecal microbiota transplantation (FMT) for C. difficile and emerging microbiome-based therapies.
: Significant updates to MASLD (Metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) and new treatments for viral hepatitis and autoimmune liver diseases.
The 12th edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease has been thoroughly revised and updated to reflect the latest advances in the field. Some of the key features of this edition include:
In addition to the textbook, several online resources are available to supplement the 12th edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease, including: s gastrointestinal and liver disease 12th edition
The release of , marks a pivotal moment for gastroenterologists, hepatologists, and internal medicine specialists worldwide. For over fifty years, this text has served as the "gold standard" or the "bible" of digestive health.
: High-speed scannable decision-making tools that summarize patient management for complex GI cases. specific summary of one of the new clinical topics like MASLD?
Deep dives into Celiac disease, Crohn’s, Ulcerative Colitis, and IBS. A new chapter dedicated to the role of
For more than half a century, Sleisenger and Fordtran's has been the definitive reference in the field, earning its place as the go-to source for gastroenterologists, hepatologists, and the entire multidisciplinary GI care team. This two-volume masterwork has consistently brought together the knowledge of hundreds of global experts to keep practitioners up to date with every aspect of GI and liver disease—from foundational basic science to the latest clinical techniques and technologies. This enduring reputation has been formally recognized, as the 12th edition has been , a testament to its indispensable quality and relevance.
Reflecting the global nomenclature change, the textbook updates its hepatology sections from Non-Alcoholic Fatty Liver Disease (NAFLD) to . It outlines the latest metabolic diagnostic criteria, non-invasive fibrotic staging biomarkers, and emergent therapeutic targets for steatohepatitis. 3. Modernized Inflammatory Bowel Disease (IBD) Therapeutics
Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 12th Edition Reflecting the global nomenclature change
In an era where medical knowledge evolves at a breakneck pace, the 12th edition arrives as an essential update, bridging the gap between cutting-edge research and bedside practice. What’s New in the 12th Edition?
: Expanded focus on MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), formerly NAFLD, along with new chapters on non-invasive fibrosis assessment and nutrition in liver disease.